CAESAREA, Israel , June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated at U.S. medical society conferences compared...
Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy
At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence-free...
No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares
Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared with prior to FDA clearance
CAESAREA, Israel , May 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
As the only FDA cleared minimally invasive treatment option for low-risk breast cancer, ProSense® is aligned with the trend toward de-escalation of breast cancer treatment—a key theme at this year's...
The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum accelerates
CAESAREA, Israel , March 26, 2026 /PRNewswire/ -- IceCure Medical Ltd . (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology...